Repligen Corp
RGEN
Key stats
- Open
- 167.71
- Day high
- 169.40
- Day low
- 163.85
- Previous close
- 172.62
- Volume
- 803.0K
- VWAP
- 167.02
- 52-week high
- 198.87
- 52-week low
- 100.99
- Market cap
- 11.03B
- Shares out
- 63.92M
- Employees
- 2,000
- Listed
- 1986
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · WALTHAM, MA · repligen.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 662
- Put open interest
- 1.1K
- Put/call
- 1.65
- At-the-money IV
- 57.5%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 170 put | 6.30 | Oct 30, 3:35 PM | 250 | 297 | 53.6% |
| 140 put | 3.00 | Oct 6, 10:10 AM | 100 | 100 | 77.9% |
| 190 put | 20.30 | Nov 5, 10:24 AM | 27 | 64 | — |
| 180 call | 1.50 | Nov 12, 9:30 AM | 14 | 31 | 63.4% |
| 180 put | 14.30 | Nov 5, 3:30 PM | 12 | 109 | 46.0% |
| 185 put | 15.40 | Oct 30, 12:08 PM | 9 | 5 | 40.5% |
Quarterly results
Massive · Oct 30, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $209.31M | $204.13M | $194.25M | $197.91M |
| Gross profit | $110.99M | $110.04M | $108.28M | $103.83M |
| Operating income | −$29.55M | $13.98M | $15.94M | $17.87M |
| Net income | −$38.43M | $5.01M | $8.33M | $13.29M |
| Diluted EPS | -0.68 | 0.09 | 0.15 | 0.23 |
| Operating cash flow | $43.10M | $32.77M | $28.30M | $25.70M |
| Assets | $2.93B | $2.95B | $2.93B | $2.95B |
| Liabilities | $834.67M | $838.15M | $825.31M | $843.57M |
| Equity | $2.09B | $2.11B | $2.11B | $2.11B |
Technicals
Massive · Nov 12, 2026- 50-day average177.18
- 200-day average145.21
- RSI (14 days)42.3
Short interest
Massive · Oct 30, 2026- Oct 30, 20267.05M shares · 4.9 days to cover
- Oct 15, 20267.15M shares · 4.9 days to cover
- Sep 30, 20267.58M shares · 6.6 days to cover
- Sep 15, 20266.71M shares · 7.1 days to cover
Related companies
MassiveNews coverage
No stories about Repligen Corp right now.